Connect with us

Technology

QC Ware Announces 2026 Q2B Copenhagen Conference Focused on the Roadmap to Quantum Value in Europe and Beyond

Published

on

QC Ware and Danish Consortium – comprising the Ministry of Foreign Affairs of Denmark, Novo Nordisk Foundation, Novo Holdings and 55 North – to host 2026 Q2B Copenhagen Conference.

Two-day conference to connect international and European quantum industry experts across AI, HPC, pharmaceutical, finance, telecommunications, automotive, and more.

COPENHAGEN, Denmark, Aug. 19, 2026 /PRNewswire/ — QC Ware, the organizer of Q2B conferences and a developer of computational chemistry and quantum computing software, today announced that the 2026 Q2B Copenhagen Conference will take place on September 9-10, 2026, in Copenhagen, Denmark. The conference is presented in joint partnership with a Danish Consortium comprising the Ministry of Foreign Affairs of Denmark, Novo Nordisk Foundation, Novo Holdings and 55 North.

As the Co-Host and Platinum Sponsor of the Q2B Copenhagen Conference, the Danish Consortium will lead strategic discussions focused on real-world quantum impact and international cooperation. Denmark has established itself as a leading European quantum hub by connecting cutting-edge research with industry adoption. Through strategic investment, public-private collaboration, and a rapidly growing quantum ecosystem, Denmark is helping strengthen Europe’s global leadership and accelerate the path from scientific breakthroughs to real-world business impact.

“Quantum innovation depends on strong international partnerships. We are proud to welcome the global quantum community to Copenhagen and connect international partners with the Danish quantum ecosystem, fostering the collaborations that will accelerate the commercial adoption of quantum technologies,” said Susanne Hyldelund, State Secretary for Trade and Investments, Ministry of Foreign Affairs of Denmark.

The conference will be held at Copenhagen’s Øksnehallen, and will explore all major quantum technologies: computing, AI, sensing, communications, and security. Attendees can expect keynotes, industry case studies, and expert panel discussions on the leading edge of quantum R&D from some of the world’s top businesses and institutions across government, academia, and Fortune 100 companies.

The conference will open with a panel of ambassadors discussing the importance of international cooperation in advancing quantum technology. The session will be moderated by Ms. Louise Lund Henneberg, Acting Director of the Department for Techplomacy at the Danish Ministry of Foreign Affairs. It will explore quantum collaboration today and in the future, the role of government in supporting the commercialisation and scaling of quantum technologies, and what still needs to happen across talent, collaboration, funding and technology innovation.

“Together with our outstanding local partners, we’re excited to showcase how the Nordic region is helping drive Europe’s leadership in the global quantum race and accelerate the journey from scientific breakthroughs to real-world impact,” said QC Ware CEO Matt Johnson.

Through keynotes, business seminars, breakout sessions, technical workshops, and panel discussions, attendees at the Q2B Copenhagen Conference will learn about the latest quantum hardware and software breakthroughs and applications in optimisation, chemistry simulations, pharmaceutical and materials discovery, error correction, and machine learning. Notable speakers include:

Lene Oddershede – CSO & Professor, Novo Nordisk Foundation

Hiro Mori – Chair of Global Consortium Alliance WG, Q-STAR

Matt Johnson – CEO, QC Ware

Lauri Sainiemi – Corporate Vice President, Fabrication, Microsoft Quantum

Peter Krogstrup – CEO, NQCP & Quantum Foundry Copenhagen

Dr. Nathan Baker – Head of Partnerships for Chemistry & Materials, Microsoft Quantum

Ellen Devereux – CTO Advisor for Quantum, Fujitsu

Anders Broo – Senior CMC Project Leader, AstraZeneca

On day two, Steven Camp, Managing Director, Quantum Investment Banking at Needham & Company, will host a Venture Capital panel with investors, including 55 North, Deep33, Quantonation, Firgun Ventures and Qbeat Ventures.

Additionally, the conference will feature several panels and sessions from real-world practitioners and experts across industries, including AstraZeneca, Boehringer Ingelheim and Merck on pharmaceuticals and NTT Data Group Corporation on telecommunications.

Q2B is dedicated to promoting and growing the quantum technologies ecosystem. One of the critical components of the conference is the Start-up Pitch Competition organised by BioInnovation Institute. On September 9, a select group of early-stage start-ups will pitch their solutions to investors, corporates, researchers, and the wider ecosystem.

Industry leaders charting the future of quantum technology adoption from companies including NVIDIA, HPE Quantum, BCG.X, Quantum Security Defense Ltd., WISER, Alliander, Chicago Quantum Exchange, Resonance and GQI, will deliver sessions on recent advancements in the field.

The Q2B Copenhagen Conference will also host a number of vendors showcasing their latest advancements in quantum technologies, including Microsoft, Classiq, Multiverse Computing, Atom Computing, Nvision Quantum Technologies, Fujitsu, Quantinuum, Kvantify, Hamamatsu Photonics, Phasecraft, ZuriQ, kiutra, C12, Qpurpose, QC Design, IQM, AWS, and more.

Find the full agenda, featured speakers, exhibitors and register to attend the Q2B 2026 Copenhagen Conference here: https://q2b.qcware.com/conference/2026-copenhagen#agenda-full

Media Contact:

Jean-Baptiste Faverjon – jb.faverjon@qcware.com 

Danish Consortium – q2bdenmark@wearetfd.com 

About QC Ware

QC Ware is a quantum computing software company. QC Ware develops applications that unlock the power of quantum computing for drug discovery, material design and other industry verticals. QC Ware’s Promethium platform provides GPU-accelerated quantum chemistry for molecular modeling and drug discovery, helping customers make better discovery decisions today while exploring the hybrid quantum-classical workflows of tomorrow. QC Ware also organizes and hosts Q2B quantum computing conferences in Japan, Europe and the United States.

Forward-Looking Statements

This press release includes forward-looking statements relating to QC Ware’s expectations, hopes, beliefs, intentions or strategies regarding the future. Forward- looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding: QC Ware’s expectations regarding the Q2B26 Copenhagen Conference, including timing, attendance, topics and discussion. These statements are based on various assumptions and on the current expectations of QC Ware’s management and are not predictions of actual events. These forward-looking statements are subject to a number of risks and uncertainties, including changes in business, market, financial, political and legal conditions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/qc-ware-announces-2026-q2b-copenhagen-conference-focused-on-the-roadmap-to-quantum-value-in-europe-and-beyond-302854133.html

SOURCE QC Ware Corp.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BioArctic and Mesenkia enter oncology research collaboration

Published

on

By

STOCKHOLM, August 19, 2026 /PRNewswire/ — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.

The collaboration combines BioArctic’s proprietary BrainTransporter™ technology with an antibody, developed with Mesenkia’s KITAIbodies® platform. The antibody targets HVEM[1], a protein found on the surface of certain glioblastoma tumor cells, including tumor stem cells. By addressing these cells, which are thought to contribute to tumor recurrence and treatment resistance, the project aims to unlock new treatment possibilities for patients with a very high unmet medical need.

Under the agreement, BioArctic will be responsible for generating a novel drug candidate by combining its BrainTransporter technology with Mesenkia’s antibody. BioArctic and Mesenkia thereafter plan to perform preclinical studies to validate the concept and, based on the results of these studies, decide on next steps.

This research collaboration represents an important step in expanding BioArctic’s BrainTransporter pipeline into oncology and further validates the platform’s potential beyond neurodegenerative diseases. It also builds on BioArctic’s core expertise in development and delivery of pharmaceuticals to the brain.

“We are excited to broaden our research and take a first step into oncology through this collaboration,” said Gunilla Osswald, Chief Executive Officer of BioArctic. “Glioblastoma remains one of the most challenging cancers to treat, with limited therapeutic options and poor prognosis for those affected. By combining our BrainTransporter technology with Mesenkia’s innovative antibody approach, we aim to target key disease-driving mechanisms to develop new ways to treat this devastating disease.”

“This agreement marks an important step for Mesenkia and creates clear opportunities to explore a new treatment strategy for patients with glioblastoma together with BioArctic. The need for new treatments is substantial, particularly given the challenge of delivering medicines to tumor cells throughout the brain. By combining Mesenkia’s antibody expertise with BioArctic’s BrainTransporter technology, we can address one of the disease’s key barriers in a new way. We look forward to advancing the concept together with BioArctic, with the long-term goal of enabling better treatment options for patients and their loved ones,” said Moa Fransson, Chief Executive Officer of Mesenkia.

The information was released for public disclosure, through the agency of the contact person below, on August 19, 2026, at 11:15 am CET.

For further information, please contact: 
BioArctic
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

Mesenkia
Moa Fransson, CEO
E-mail: moa.fransson@mesenkia.com
Telephone: +46 072 211 71 61

About Mesenkia Therapeutics AB

Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma. Mesenkia is founded on world leading science from Uppsala University and the University of Tokyo originating from decades of collaborations dedicated to finding the root cause for tumor pathogenesis. The company’s lead program targets glioblastoma, while their KITAIbodies® are designed to enable future therapeutics across multiple indications and modalities. Through strategic collaborations with pharmaceutical companies, Mesenkia aims to accelerate drug development and create value for patients worldwide.

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

[1] Herpes virus entry mediator, a protein that is part of the tumor necrosis factor (TNF) receptor superfamily.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/bioarctic-and-mesenkia-enter-oncology-research-collaboration,c4385181

The following files are available for download:

https://mb.cision.com/Main/9978/4385181/4224986.pdf

BioArctic and Mesenkia enter oncology research collaboration

View original content:https://www.prnewswire.co.uk/news-releases/bioarctic-and-mesenkia-enter-oncology-research-collaboration-302855134.html

Continue Reading

Technology

Oppenheimer Hosts Fifth Annual Next-Gen Peer-to-Peer Forum

Published

on

By

Approximately 60 Financial Advisors Representing $7.2 Billion in Client Assets Gather in New York City

Annual Program Reflects Oppenheimer’s Continued Investment in the Development and Long-Term Success of Its Next Generation of Advisors

NEW YORK, Aug. 19, 2026 /PRNewswire/ — Oppenheimer & Co. Inc. (Oppenheimer), a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), recently hosted its fifth annual Next-Gen Peer-to-Peer Forum in New York City, bringing together approximately 60 Financial Advisors from across the country.

Held at One World Trade Center overlooking Lower Manhattan, the program gave attendees an opportunity to exchange ideas, discuss common challenges and learn from one another. Collectively, the participating advisors represent approximately $7.2 billion in assets under management and $41 million in annual revenue.

“Now in its fifth year, the Next-Gen Peer-to-Peer Forum reflects Oppenheimer’s commitment to investing the time and resources into developing the next generation of advisors,” said Ed Harrington, Executive Vice President and Head of Oppenheimer’s Private Client Division. “The event brings together advisors who are building substantial businesses but at the same time navigating similar challenges. By giving them a setting to speak candidly and share practical insights, we help them strengthen how they serve clients and continue growing their practices.”

Oppenheimer developed the Next-Gen Peer-to-Peer Forum to help emerging leaders develop the skills, relationships and perspective required to build successful careers. The program forms part of the firm’s broader investment in the long-term success of its advisor workforce.

Discussions throughout the program focused on the issues shaping the future of the wealth management industry and the decisions that will influence the growth of attendees’ businesses. Topics included building scalable practices, developing effective teams, incorporating artificial intelligence and other technologies to improve efficiency, differentiating investment advice and positioning practices to meet the evolving expectations of future generations of clients.

The Forum also encouraged attendees to challenge conventional thinking and offer candid perspectives on what it takes to compete in a rapidly changing industry. Their engagement, thoughtfulness and willingness to contribute underscored the strength of Oppenheimer’s next generation of advisors.

“The Peer-to-Peer Forum works because the advisors drive the conversation,” said Nicholas Siconolfi, Managing Director and Head of National Sales for Oppenheimer’s Private Client Division. “Each of our Next Gen advisors brings a unique perspective, but they all share a common goal of continuously enhancing the client experience while building practices designed to endure and adapt. The ideas exchanged throughout the forum help shape the future of our firm. Our advisors learn from one another, and as leaders, we gain invaluable firsthand insight into what they need to succeed. Every year, this event reinforces that the future of our firm is in very capable hands.”

“Oppenheimer is an ideal place for advisors to build and grow their careers over time,” Harrington added. “We are committed to giving talented advisors the tools, resources and support they need to succeed, and the Next-Gen Peer-to-Peer Forum is an important part of that commitment. It helps emerging leaders strengthen their professional networks, develop as business owners and play a meaningful role in the future of the firm. We believe the most important investment we can make is in our people. The firms that endure are those that develop talent, not simply acquire it. By bringing together advisors who are committed to building exceptional practices, we are helping to develop the next generation of leaders while strengthening the long-term future of Oppenheimer and the clients we serve.”

About Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc., a major subsidiary of Oppenheimer Holdings Inc. (NYSE: OPY), is a leading middle-market investment bank and full-service broker-dealer. The firm provides a broad range of investment banking, securities brokerage and wealth management services to corporations, institutions and high-net-worth individuals.

Media Contact:
Mitch Manning
Haven Tower Group LLC
424 317 4858
mmanning@haventower.com

View original content:https://www.prnewswire.com/news-releases/oppenheimer-hosts-fifth-annual-next-gen-peer-to-peer-forum-302854634.html

SOURCE Oppenheimer & Co. Inc.

Continue Reading

Technology

NGP VAN Launches Navigator, Bringing the Power of Natural-Language Search to the Progressive Ecosystem’s Most Powerful CRM

Published

on

By

Navigator lets campaign staff search their CRM the way they think by simply describing who they want to find.

WASHINGTON, Aug. 19, 2026 /PRNewswire/ — NGP VAN today launched Navigator, a natural-language search assistant built directly into Create a List (CAL), NGP’s core segmentation tool. Navigator uses AI behind the scenes to turn plain-language requests into the filters and criteria needed to find the right people. Create a List allows campaigns and organizations to search their databases and identify specific groups of supporters based on their giving, activity, contact information, and other criteria. It’s the foundational tool for surfacing the most critical data in order to take action.

Beginning today, a fundraiser or digital director can go into NGP’s Create a List tool and simply describe the people they are looking for using natural language. Navigator translates that request into the appropriate search criteria. The fundraiser can see exactly what Navigator has selected, change anything they want, and then run the search.

NGP VAN is developing additional Navigator capabilities to make other everyday campaign tasks easier, including bulk uploading data and analyzing canvassing notes, along with more ways to use Navigator to create lists.

“Our mission has always been to empower the people driving the progressive movement forward – the organizers, fundraisers and digital teams doing hard work to engage people on the ground. We’re not interested in duct-taping AI into our products just to say we can,” said NGP VAN General Manager Chelsea Peterson Thompson. “The test for us has always been simple: Will this save a campaign time? Does this help a first-time candidate get started? Can an organizer or fundraiser use this to have the right conversation with the right person at the right time? Ultimately, does it help elect more Democrats? If the answer is yes, that’s where we want to invest.”

For decades, Democratic and progressive campaigns have used NGP VAN to track the people who power the progressive ecosystem: voters, volunteers, activists, and donors. Teams use this critical information to run data-driven campaigns and programs.

Traditional software has forced users to learn and then translate searches into the system’s language through a combination of searches, filters, and criteria, not their own. For first-time organizers, fundraisers, or candidates, it slows critical work down. Today, NGP VAN is starting to break down those barriers to the first knocks, calls, and conversations.

“Navigator is about meeting our users where they already do their work and making it easier to find the right people,” said Lou Levine, Senior Vice President at NGP VAN. “You tell Navigator who you’re trying to find, it builds the search, and then you can run it as-is or tweak anything you want. This is just the beginning of how we’re thinking about making the tools campaigns already rely on easier and more intuitive to use.”

Importantly, the user stays in control. Navigator is an optional starting point inside the existing Create a List page. Users can use it, skip it or switch to a manual search at any point. Every criterion Navigator generates is visible and editable, and nothing runs without the user’s approval. Previously saved searches are unaffected.

At launch, Navigator can work with eight commonly used search options: Activist Codes, Addresses, Email, Online Forms, Recurring Commitments, Contributions, Contribution Summaries and My Saved Lists.

Navigator is available beginning today to NGP VAN users with Create a List access in NGP databases, with additional capabilities coming soon.

About NGP VAN
NGP VAN is the winningest technology platform in the history of democratic and progressive causes, working tirelessly to innovate and advance the technology our clients rely on to bolster our democracy. A proud unionized employer, we help power the trailblazers, campaigners, and advocates fighting up and down the ticket for equality, racial justice, reproductive freedom, democracy, climate reform, and more— including the national Democratic committees and progressive organizations, thousands of Democratic campaigns, hundreds of labor unions, advocacy organizations, progressive and non-partisan PACs, and other organizations.

Press Contact:
Simone Hassan-Bey
NGP VAN
press@ngpvan.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ngp-van-launches-navigator-bringing-the-power-of-natural-language-search-to-the-progressive-ecosystems-most-powerful-crm-302854874.html

SOURCE NGP VAN

Continue Reading

Trending